Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 10, 2015 7:21 AM ET

Life Sciences Tools and Services

Company Overview of Chromocell Corporation

Company Overview

Chromocell Corporation, a life sciences company, discovers and develops flavors and functional ingredients, and therapeutics based on Chromovert technology. Its Chromovert technology enables the company to use naturally occurring systems that mimic human biology as a part of its discovery platform to provide practical solutions to problems in food and pharmaceuticals. The company specializes in molecular and cell biology, assay development, screening, and medicinal chemistry areas. It also focuses on identifying new drugs/therapeutic compounds for pain relief, anxiety treatment, and treatment of respiratory disorders. In addition, Chromocell Corporation develops flavor ingredients and natura...

685 U.S. Highway One

North Brunswick, NJ 08902

United States

Founded in 2002





Key Executives for Chromocell Corporation

Chief Executive Officer
Head of Business Development and Associate Director
Senior Vice President of Therapeutics
Age: 61
Senior Vice President of Flavors and Natural Products
Vice President of Legal Affairs and Corporate Development
Compensation as of Fiscal Year 2015.

Chromocell Corporation Key Developments

Astellas Pharma and Chromocell Enter into Drug Development Collaboration for Neuropathic Pain

Astellas Pharma, Inc. and Chromocell Corporation have entered into a collaboration to develop and commercialise treatments for neuropathic pain and other pain conditions, the companies said in a statement. Under the agreement, Astellas receives global rights to commercialise pain treatment CC8464, as well as product candidates identified through Chromocell's Chromovert technology platform. Chromocell will receive an upfront payment of 15 million and is eligible to receive over 500 million in development and commercial milestones, as well as double-digit sales royalties from CC8464. In addition, Chromocell may suggest and initiate studies for additional indications, such as rare diseases and non-oral formulations of the drug candidate. Astellas would be eligible for inclusion into these additional developments, which would result in further payments for Chromocell and US co-promotion rights in some cases.

Astellas and Chromocell Announce License and Collaboration Agreement to Develop and Commercialize New Therapies to Treat Neuropathic Pain

Astellas Pharma Inc. and Chromocell Corporation announced that they have entered into a license and collaboration agreement for the development and commercialization of therapeutics to treat neuropathic and other pain conditions. Astellas obtains worldwide rights to commercialize CC8464 and back-up drug candidates to treat pain that have been identified through Chromocell's Chromovert® technology platform. Chromocell receives $15 million as an up-front payment and is eligible to receive over $500 million, including development and commercial milestones, as well as double digit royalties on sales if CC8464 is successfully commercialized. Chromocell will conduct all development of CC8464 through the initial Phase 2a proof-of-concept clinical trial in neuropathic pain. Astellas will lead all further development activities through to commercialization of CC8464 for the treatment of peripheral neuropathic pain. Aside from those development activities, Chromocell may propose, and may initiate, studies for certain additional indications such as rare diseases and non-oral formulations of the drug candidate. Astellas has the right to opt-in for development for such additional indications, which triggers additional payments to Chromocell, and, in certain cases, co-promotion rights in the U.S. NaV1.7 is an ion channel, involved in the transmission of pain. Chromocell's lead compound, CC8464, is an oral, peripherally-acting inhibitor of NaV1.7, which may prove to be efficacious in several large unmet or poorly served chronic pain markets as well as rare, currently untreated diseases. Chromocell anticipates filing an IND for CC8464 in early 2016.

Chromocell Corporation Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014

Chromocell Corporation Presents at BioNJ 2014 International BioPartnering Conference, Apr-10-2014 . Venue: The Westin Princeton, Forrestal Village, New Jersey, United States. Speakers: Christian Kopfli, Chief Executive Officer.

Similar Private Companies By Industry

Company Name Region
Regenerative Medical Solutions, Inc. United States
BioreclamationIVT United States
Clinical Supplies Management, Inc. United States
Virgin Instruments Corp. United States
Datasci, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Chromocell Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at